5-to 30-gauge needle. The needle should be directed at the center of the base of the wart and at an angle almost parallel to the plane of the skin (approximately that in the commonly used PPD test). This will deliver the interferon to the dermal core of the lesion, infiltrating the lesion and causing a small wheal. Care should be taken not to go beneath the lesion too deeply; subcutaneous injection should be avoided, since this area is below the base of the lesion. Do not inject too superficially since this will result in possible leakage, infiltrating only the keratinized layer and not the dermal core.
AIDS-Related Kaposi's Sarcoma
(see DOSAGE and ADMINISTRATION, General section)
Dose
The recommended dose of INTRON A for Kaposi's Sarcoma is 30 million IU/m2/dose administered subcutaneously or intramuscularly three times a week until disease progression or maximal response has been achieved after 16 weeks of treatment. Dose reduction is frequently required (see Dose Adjustment below).
Dosage Forms for this Indication Dosage Form Concentration Route
Powder 50 MIU 50 MIU/mL IM, SC
NOTE: INTRON A Solution for Injection either in vials or in Multidose Pens should NOT be used for AIDS-Related Kaposi's Sarcoma.
NOTE: INTRON A Powder for Injection does not contain a preservative. The vial must be discarded after reconstitution and withdrawal of a single dose.
Dose Adjustment
INTRON A dose should be reduced by 50% or withheld for severe adverse reactions.
INTRON A may be resumed at a reduced dose if severe adverse reactions abate with interruption of dosing.
INTRON A should be permanently discontinued if severe adverse reactions persist or if they recur in patients receiving a reduced dose.
Chronic Hepatitis C
(see DOSAGE and ADMINISTRATION, General section)
Dose
The recommended dose of INTRON A for the treatment of chronic hepatitis C is 3 million IU three times a week (TIW) administered subcutaneously or intramuscularly. In patients tolerating therapy with normalization of ALT at 16 weeks of treatment, INTRON A therapy should be extended to 18 to 24 months (72 to 96 weeks) at 3 million IU TIW to improve the sustained response rate (see CLINICAL PHARMACOLOGY, Chronic Hepatitis C section). Patients who do not normalize their ALTs or have persistently high levels of HCV RNA after 16 weeks of therapy rarely achieve a sustained response with extension of treatment. Consideration should be given to discontinuing these patients from therapy.
When INTRON A is administered in combination with REBETOL®, patients with impaired renal function and/or those over the age of 50 should be carefully monitored with respect to the development of anemia. See REBETOL package insert for dosing when used in combination with REBETOL for adults and pediatric patients.
Dosage Forms for this Indication Dosage Form Concentration Route Fixed Doses
Solution 18 MIU multidose 6 MIU/mL IM, SC N/A
Pen 3 MIU/dose multidose 15 MIU/mL SC 1.5, 3.0
Dose adjustment
If severe adverse reactions develop during INTRON A treatment, the dose should be modified (50% reduction) or therapy should be temporarily discontinued until the adverse reactions abate. If intolerance persists after dose adjustment, INTRON A therapy should be discontinued.
Chronic Hepatitis B Adults
(see DOSAGE and ADMINISTRATION, General section)
Dose
The recommended dose of INTRON A for the treatment of chronic hepat
